Skip to main content
. 2021 Nov 16;297(6):101420. doi: 10.1016/j.jbc.2021.101420

Figure 3.

Figure 3

HER2/PD-L1 BsAb blocked PD1/PD-L1 interaction.A, BsAb suppressed PD-L1 interaction with PD-1 in ELISA. Avelumab and trastuzumab were used as positive and negative controls, respectively. B, IFN-γ secretion induced by BsAb in mixed lymphocyte reaction (MLR) assays. CD4+ T cells were cocultured with allogeneic DCs in the presence of BsAb, avelumab, or isotype for 6 days. Supernatants were harvested on day 5 to measure IFN-γ secretion by ELISA. C, BsAb overcame PD-L1-mediated suppression of T-cell activation. The effects of BsAb treatment on IFN-γ secretion in primary T cell activation induced by anti-CD3, anti-CD28 and PD-L1. ∗p < 0.05 as indicated by Student’s t test. Data were represented as mean ± STE.